Despite the high efficacy of SMO inhibition in patients with basal cell carcinoma and medulloblastoma, which are characterized by the presence of Hh mutations, the efficacy of these inhibitors in ligand-dependent Hh-activated cancer types such as PCa has not yet been established. The gene discussed is SMO; the disease is posterior cortical atrophy.